

- **Name:** **Joohyuk Sohn**
- **Current Position & Affiliation:** **Professor/Chief of Medical Oncology,  
Division of Medical Oncology**
- **Country:** **Republic of Korea**

---

**• Educational Background:**

1987-1989	Department of Pre-medical Science Yonsei University College of Medicine, Seoul, Korea.
1989-1993	Degree of Medical Doctor, Yonsei University College of Medicine, Seoul, Korea
2000-2001	Master of Science, Yonsei University College of Medicine, Seoul, Korea
2003-2008	Philosophiae Doctor, Yonsei University College of Medicine, Seoul, Korea

---

**• Professional Experience:**

1993-1994	Rotating Internship, Yonsei University College of Medicine, Severance
1994-1997	Hospital
1998-2002	Military Doctor, Wondang, Kyungi Do, Korea Residency in Internal Medicine
2002-2004	Yonsei University College of Medicine, Severance Hospital Research Fellowship & Clinical Fellowship in Medical Oncology Division of Hemato-Oncology, Department of Medicine, Yonsei Cancer
2004-2006	Center Yonsei University College of Medicine, Seoul, Korea Instructor
2006-2010	Yonsei Cancer Center Yonsei University College of Medicine, Seoul, Korea Assistant Professor
2010-2015	Yonsei Cancer Center Yonsei University College of Medicine, Seoul, Korea Associate Professor
2011-2013	Yonsei Cancer Center Yonsei University College of Medicine, Seoul, Korea Visiting Associate Professor
2015- 2017-	Breast Medical Oncology & Systems Biology MD Anderson Cancer Center, Houston, Texas, USA Professor Chief, Division of Medical Oncology Yonsei Cancer Center

Yonsei University College of Medicine  
Seoul, Korea

• **Professional Organizations:**

Yonsei University College of Medicine

• **Main Scientific Publications:**

**Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older** Kim MH, Kim GM, Kim JH, Kim JY, Park HS, Park S, Cho YU, Park BW, Kim SI, Sohn J. *Breast Cancer Res Treat.* 2020 Feb;179(3):687-697.

**CD44/CD24 and aldehyd dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator** Yong Wha Moon, Hee-Jung An, Ja Seung Koo, Gun Min Kim, Hyunju Han, Seho Park, Seung Il Kim, Hyung Seok Park, Sewha Kim, Seung Ki Kim, Seung Ah Lee, Sohyun Hwang, Gun Woo Son, Joohyuk Sohn. *Oncotarget* 2017. December 21, 2017.

**An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer** In Hae Park, Joo hyuk Sohn, Sung Bae Kim, Keun Seok Lee, Joo Seop Chung, Soo Hyeon Lee, Tae You Kim, Kyung Hae Jung, Eun Kyung Cho, Yang Soo Kim, Hong Suk Song, Jae Hong Seo, Hun Mo Ryoo, Sun Ah Lee, So Young Yoon, Chul Soo Kim, Yong Tai Kim, Si Young Kim, Mi Ryung Jin, Jungsil Ro. *CANCER RESEARCH AND TREATMENT* 49 : 569-577. 2016 Sep 12.